Although we are still in the early stages of blood-based AD biomarker development, many studies have reported the correlation between blood-based and core CSF biomarkers and brain imaging (e.g., amyloid PET, tau PET, and FDG PET) (Table 1). Here, MAPT is linked to Alzheimer disease.